Compare · INVO vs RMD
INVO vs RMD
Side-by-side comparison of INVO BioScience Inc. (INVO) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INVO and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD carries a market cap of $33.69B.
- RMD has hit the wire 12 times in the past 4 weeks while INVO has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 2 for INVO).
- Company
- INVO BioScience Inc.
- ResMed Inc.
- Price
- -
- $239.53+0.16%
- Market cap
- -
- $33.69B
- 1M return
- -
- -1.16%
- 1Y return
- -
- -2.13%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 12
- Recent ratings
- 2
- 25
INVO BioScience Inc.
INVO Bioscience, Inc., a medical device company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a patented intravaginal culture system used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. The company was founded in 2007 and is based in Sarasota, Massachusetts.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest INVO
- NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma
- SEC Form RW filed by INVO BioScience Inc.
- INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
- INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits
- INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
- INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- INVO BioScience Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits
- INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- INVO BioScience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by INVO BioScience Inc.
Latest RMD
- Chairman and CEO Farrell Michael J. covered exercise/tax liability with 8,111 units of ResMed Common Stock, decreasing direct ownership by 2% to 471,774 units (SEC Form 4) (tax withholding)
- Chief Financial Officer Bloomer Aaron covered exercise/tax liability with 1,095 units of ResMed Common Stock, decreasing direct ownership by 12% to 7,977 units (SEC Form 4) to satisfy withholding tax
- Director Farrell Peter C covered exercise/tax liability with 169 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 51,634 units (SEC Form 4) (withholding obligation)
- Director De Witte Jan covered exercise/tax liability with 60 units of ResMed Common Stock, decreasing direct ownership by 1% to 4,201 units (SEC Form 4) (for tax liability)
- Director Gill Harjit covered exercise/tax liability with 36 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 10,904 units (SEC Form 4) (withholding tax)
- Global General Counsel Rider Michael J covered exercise/tax liability with 1,944 units of ResMed Common Stock, decreasing direct ownership by 16% to 10,417 units (SEC Form 4) (withholding obligation)
- Chairman and CEO Farrell Michael J. exercised 4,993 units of ResMed Common Stock at a strike of $146.34 and sold $1,175,089 worth of ResMed Common Stock (4,993 units at $235.35) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.